Stockscreener 앱 받기
2.38
0.85%
0.03
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Notice to Long-Term Shareholders of Akero Therapeutics, - GlobeNewswire
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is I - TradingView
Why Kyverna Therapeutics Stock Is Sinking - MSN
Investors Who Lost Money on Kyverna Therapeutics, Inc. (KYTX) Should Contact Levi & Korsinsky About Pending Class ActionKYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More Information – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics stock hits 52-week low at $2.24 - Investing.com
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
Kyverna Therapeutics stock hits 52-week low at $2.24 By Investing.com - Investing.com South Africa
Notice to Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Clai - Morningstar
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lupus Nephritis Clinical and Non-Clinical Studies, Key - openPR
GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna - Business Wire
Notice to Long-Term Shareholders of Archer-Daniels-Midland - GlobeNewswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: - GlobeNewswire
KYTX stock touches 52-week low at $2.49 amid market challenges - Investing.com Australia
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Rhumbline Advisers Purchases 6,153 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics stock hits 52-week low at $2.64 By Investing.com - Investing.com Australia
Kyverna Therapeutics to Present at the Leerink Partners Global B - GuruFocus.com
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PR Newswire
Kyverna Therapeutics stock hits 52-week low at $2.64 - Investing.com
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc. (KYTX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Kyverna Therapeutics To Present At The Leerink Partners Global Biopharma Conference - MENAFN.COM
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Head-To-Head Survey: Pluri (NASDAQ:PLUR) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
3 US Penny Stocks With Market Caps Under $200M - Yahoo Finance
KYTX stock touches 52-week low at $2.78 amid sharp annual decline - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $25.71 Consensus Price Target from Analysts - Defense World
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Leerink Partnrs Issues Optimistic Estimate for KYTX Earnings - MarketBeat
KYTX stock touches 52-week low at $2.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Equities Analysts Set Expectations for KYTX FY2025 Earnings - Defense World
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock - MSN
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Kilgore News Herald
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com
2025-02-07 | FINAL REMINDER KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Kyverna Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit | NDAQ:KYTX | Press Release - Stockhouse Publishing
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - TradingView
1.39%
0.27%
자본화:
|
볼륨(24시간):